2024 ended on a strong note; 2025 outlook surpassed expectations
05/02/25 -"The Q4 earnings were ahead of consensus estimates, driven by a robust showing across key focus areas. Moreover, the 2025 outlook was better than the street’s expectations. While we expect ..."
Pages
65
Language
English
Published on
05/02/25
You may also be interested by these reports :
13/11/25
The Q3 results exceeded the street’s expectations, driven by healthy top-line growth across all segments and a profitability beat (also aided by a ...
12/11/25
The Q3 profitability beat was driven by Crop Science, though Pharmaceuticals witnessed lower operating profits. Also, the management maintained its ...
10/11/25
The US government has agreed with Novo and Lilly to lower their weight-loss drugs’ prices, mainly in return for a three-year tariff exemption and ...
07/11/25
Genmab’s Q3 results surpassed the street’s expectations, driven by robust performance across most offerings, resulting in solid profitability ...